Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Peter Lowry Insider Profile
11 Followers
Peter Lowry, Director at RepliCel Life Sciences, holds 1.19M shares in RepliCel Life Sciences (Ticker: REPCF). Most recently, Peter Lowry Bought $294,444 shares of RepliCel Life Sciences on Jan 19, 2023 for an estimated value of 26.50K.
Profitable Transactions
1 out of 5 Profitable Transactions
Average Return
-17.30%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Peter Lowry holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Aug 21, 2020 - Aug 21, 2021
Return:+60.70%
The most profitable trade made by Peter Lowry
Peter Lowry's Trading History
List of latest transactions for each holding click on a transaction to see Peter Lowry's performance on stock
You May Also Like
Peter Lowry insider profile FAQ
What is the percentage of profitable transactions made by Peter Lowry?
The percentage of profitable transactions made by Peter Lowry is 20%.
What is the average return per transaction made by Peter Lowry?
The average return per transaction made by Peter Lowry is -17.30%.
What stocks does Peter Lowry hold?
Peter Lowry holds: REPCF stocks.
What was Peter Lowry’s latest transaction?
Peter Lowry latest transaction was an Informative Buy of $26.50K.
What was Peter Lowry's most profitable transaction?
Peter Lowry’s most profitable transaction was an Informative Buy of REPCF stock on August 21, 2020. The return on the trade was 60.70%.
What is Peter Lowry's role in RepliCel Life Sciences?
Peter Lowry's role in RepliCel Life Sciences is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.